{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:14:55Z","timestamp":1792199695244,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Olanzapine has exhibited efficacy as an antiemetic agent when used with 5-HT<jats:sub>3<\/jats:sub> receptor antagonists, dexamethasone, and NK<jats:sub>1<\/jats:sub> receptor antagonists for patients receiving highly emetogenic chemotherapy. In addition, several studies have reported the efficacy or safety of olanzapine in patients receiving moderately emetogenic chemotherapy, including carboplatin, irinotecan, and oxaliplatin. However, no reports of olanzapine use have focused on patients receiving oxaliplatin-based chemotherapy. Therefore, we analyzed the safety of antiemetic therapy using olanzapine, palonosetron, aprepitant, and dexamethasone in colorectal cancer patients undergoing oxaliplatin-based chemotherapy. This study was a prospective phase II single-institution study of 40 patients (median age 60\u00a0years, 23 patients were male). The primary endpoint was the incidence of adverse events, and the exploratory endpoints were the rate of chemotherapy-induced nausea and vomiting. Almost all patients (90%) had a performance status of 0. All patients received the scheduled antiemetic therapy. The most common adverse event was somnolence (n\u2009=\u20097 patients, 17.5%). All adverse events were grade 1. Thirty-six patients were included in the exploratory analysis of efficacy. No patients experienced vomiting during the first 120\u00a0h after chemotherapy, and complete response and complete control were both 86.1%. The rate of total control was 55.6% during the same time period. Olanzapine use with 5-HT<jats:sub>3<\/jats:sub> receptor antagonists, dexamethasone, and NK<jats:sub>1<\/jats:sub> receptor antagonists was safe for colorectal cancer patients receiving oxaliplatin-based chemotherapy.<\/jats:p>","DOI":"10.1038\/s41598-021-84225-6","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T11:04:11Z","timestamp":1614251051000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A phase II study of the safety of olanzapine for oxaliplatin based chemotherapy in coloraectal patients"],"prefix":"10.1038","volume":"11","author":[{"given":"Junichi","family":"Nishimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotsugu","family":"Haraguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Ushigome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Shinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Asukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisaku","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keijiro","family":"Sugimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Ohue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"84225_CR1","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.ejca.2015.03.024","volume":"51","author":"J Nishimura","year":"2015","unstructured":"Nishimura, J. et al. Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): A multicentre, randomised, controlled phase 3 trial. Eur. J. Cancer 51, 1274\u20131282. https:\/\/doi.org\/10.1016\/j.ejca.2015.03.024 (2015).","journal-title":"Eur. J. Cancer"},{"key":"84225_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s10147-016-1022-9","volume":"22","author":"H Takemoto","year":"2017","unstructured":"Takemoto, H. et al. Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: Analysis of risk factors for vomiting and nausea. Int. J. Clin. Oncol. 22, 88\u201395. https:\/\/doi.org\/10.1007\/s10147-016-1022-9 (2017).","journal-title":"Int. J. Clin. Oncol."},{"key":"84225_CR3","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/s0885-3924(02)00391-3","volume":"23","author":"SD Passik","year":"2002","unstructured":"Passik, S. D. et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J. Pain Symptom Manag. 23, 526\u2013532. https:\/\/doi.org\/10.1016\/s0885-3924(02)00391-3 (2002).","journal-title":"J. Pain Symptom Manag."},{"key":"84225_CR4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00520-004-0755-6","volume":"13","author":"RM Navari","year":"2005","unstructured":"Navari, R. M. et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study. Support. Care Cancer 13, 529\u2013534. https:\/\/doi.org\/10.1007\/s00520-004-0755-6 (2005).","journal-title":"Support. Care Cancer"},{"key":"84225_CR5","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2017.577","author":"SY Jeon","year":"2018","unstructured":"Jeon, S. Y. et al. A randomized, double-blind, placebo-controlled study of the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy: Results of the Korean South West Oncology Group (KSWOG) Study. Cancer Res. Treat. https:\/\/doi.org\/10.4143\/crt.2017.577 (2018).","journal-title":"Cancer Res. Treat."},{"key":"84225_CR6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto, H. et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 242\u2013249. https:\/\/doi.org\/10.1016\/S1470-2045(19)30678-3 (2020).","journal-title":"Lancet Oncol."},{"key":"84225_CR7","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh, P. J. et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 35, 3240\u20133261. https:\/\/doi.org\/10.1200\/JCO.2017.74.4789 (2017).","journal-title":"J. Clin. Oncol."},{"key":"84225_CR8","unstructured":"NCCN. NCCN clinical practice guidelines in oncology version 2. Antiemesis. National Comprehensive Cancer Network (2020)."},{"key":"84225_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1056\/NEJM200107123450201","volume":"345","author":"RB Nadelman","year":"2001","unstructured":"Nadelman, R. B. et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N. Engl. J. Med. 345, 79\u201384. https:\/\/doi.org\/10.1056\/NEJM200107123450201 (2001).","journal-title":"N. Engl. J. Med."},{"key":"84225_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari, R. M. et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N. Engl. J. Med. 375, 134\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa1515725 (2016).","journal-title":"N. Engl. J. Med."},{"key":"84225_CR11","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.bbmt.2018.06.005","volume":"24","author":"AB Clemmons","year":"2018","unstructured":"Clemmons, A. B. et al. Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: The FOND-O Trial. Biol. Blood Marrow Transpl. 24, 2065\u20132071. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.005 (2018).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"84225_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00280-019-03868-5","volume":"84","author":"K Tanaka","year":"2019","unstructured":"Tanaka, K. et al. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. Cancer Chemother. Pharmacol. 84, 147\u2013153. https:\/\/doi.org\/10.1007\/s00280-019-03868-5 (2019).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"84225_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00520-015-2829-z","volume":"24","author":"M Abe","year":"2016","unstructured":"Abe, M. et al. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Support. Care Cancer 24, 675\u2013682. https:\/\/doi.org\/10.1007\/s00520-015-2829-z (2016).","journal-title":"Support. Care Cancer"},{"key":"84225_CR14","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/jjco\/hyx084","volume":"47","author":"K Nakashima","year":"2017","unstructured":"Nakashima, K. et al. A phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy. Jpn. J. Clin. Oncol. 47, 840\u2013843. https:\/\/doi.org\/10.1093\/jjco\/hyx084 (2017).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"84225_CR15","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","volume":"23","author":"T Yanai","year":"2018","unstructured":"Yanai, T. et al. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int. J. Clin. Oncol. 23, 382\u2013388. https:\/\/doi.org\/10.1007\/s10147-017-1200-4 (2018).","journal-title":"Int. J. Clin. Oncol."},{"key":"84225_CR16","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/annonc\/mdl137","volume":"17","author":"MS Aapro","year":"2006","unstructured":"Aapro, M. S. et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann. Oncol. 17, 1441\u20131449. https:\/\/doi.org\/10.1093\/annonc\/mdl137 (2006).","journal-title":"Ann. Oncol."},{"key":"84225_CR17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/annonc\/mdh047","volume":"15","author":"P Eisenberg","year":"2004","unstructured":"Eisenberg, P., MacKintosh, F. R., Ritch, P., Cornett, P. A. & Macciocchi, A. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: A dose-ranging clinical study. Ann. Oncol. 15, 330\u2013337. https:\/\/doi.org\/10.1093\/annonc\/mdh047 (2004).","journal-title":"Ann. Oncol."},{"key":"84225_CR18","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/annonc\/mdg417","volume":"14","author":"R Gralla","year":"2003","unstructured":"Gralla, R. et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol. 14, 1570\u20131577. https:\/\/doi.org\/10.1093\/annonc\/mdg417 (2003).","journal-title":"Ann. Oncol."},{"key":"84225_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","volume":"10","author":"M Saito","year":"2009","unstructured":"Saito, M. et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 10, 115\u2013124. https:\/\/doi.org\/10.1016\/S1470-2045(08)70313-9 (2009).","journal-title":"Lancet Oncol."},{"key":"84225_CR20","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00520-014-2175-6","volume":"22","author":"M Popovic","year":"2014","unstructured":"Popovic, M. et al. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): A systematic review and meta-analysis of randomized controlled trials. Support. Care Cancer 22, 1685\u20131697. https:\/\/doi.org\/10.1007\/s00520-014-2175-6 (2014).","journal-title":"Support. Care Cancer"},{"key":"84225_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.21037\/apm.2018.03.09","volume":"7","author":"R Chow","year":"2018","unstructured":"Chow, R. et al. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis of randomized controlled trials. Ann. Palliat. Med. 7, 221\u2013233. https:\/\/doi.org\/10.21037\/apm.2018.03.09 (2018).","journal-title":"Ann. Palliat. Med."},{"key":"84225_CR22","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/annonc\/mdw220","volume":"27","author":"K Suzuki","year":"2016","unstructured":"Suzuki, K. et al. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann. Oncol. 27, 1601\u20131606. https:\/\/doi.org\/10.1093\/annonc\/mdw220 (2016).","journal-title":"Ann. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84225-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84225-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84225-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T04:07:27Z","timestamp":1670040447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84225-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["84225"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-84225-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]},"assertion":[{"value":"30 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4547"}}